Proteome Systems Limited, a leading proteomics technology and discovery company, announced the release of ProteomIQ, an integrated comprehensive solution designed to accelerate proteomics research and the discovery of new drugs to treat diseases such as cancer, infectious diseases and others.

ProteomIQ brings together niche sample preparation and analytical technologies with enterprise level computing and extensive training and support programs to offer an end-to-end solution for proteomics research.

Marc Wilkins, executive vice president, Bioinformatics, Proteome Systems said: "We have created ProteomIQ from the ground up for proteomics, combining the latest proteomics technology into one seamless platform. The combination of separation technology, robotics, mass spectrometry and enterprise level computing is unique to ProteomIQ, which delivers comprehensive outcomes through its ability to decipher proteomic complexity."

Alliances with key partners such as IBM, Shimadzu Biotech, Millipore, Sigma-Aldrich and ThermoFinnigan enabled Proteome Systems to accelerate the development of ProteomIQ.

Keith Williams, CEO, Proteome Systems said "ProteomIQ will revolutionize and accelerate research in the pharmaceutical and biotechnology sectors, through its broad application in the discovery of diagnostic and prognostic markers, and an ability to identify and validate drug targets.

"Our technology has been developed by practitioners of proteomics, specifically for proteome research, and has been rigorously tested in our in-house projects in cystic fibrosis, cancer, infectious diseases and aging. Our ability to test our approaches in demanding in-house discovery programs sets us apart from other vendors of proteomic technology," he said.

ProteomIQ includes patented technology for protein separation, analysis and informatics, which together delivers faster, more reproducible results. This empowers researchers to focus on their discovery outcomes while ProteomIQ produces data and assembles it into useful biological information. ProteomIQ is integrated via a sophisticated informatics package that includes BioinformatIQT, a web-based intranet application that controls laboratory instrumentation and centralizes all research outcomes into an IBM DB2 database software hosted on IBM eServer pSeries systems. BioinformatIQ provides sophisticated analysis tools that allow information and projects to be shared between sites.

Mike Svinte, vice president of worldwide business development for IBM Life Sciences said: "Proteome Systems has delivered a powerful solution for rapidly deciphering complex protein data. ProteomIQ brings together leading edge technologies, including an information technology infrastructure based on IBM eServer and DB2 data management systems, that will support proteomic research today and scale to meet future requirements."